Introduction {#s1}
============

The incidence of spontaneous pregnancy loss has been estimated to be 30% [@pone.0095803-Wilcox1]. However, less than 5% of women will experience two or more consecutive pregnancy losses [@pone.0095803-Stirrat1]. Therefore, the loss of two or more clinically recognized pregnancies is considered a distinct disorder and defined as recurrent pregnancy loss (RPL) for additional evaluation and treatment [@pone.0095803-Practice1]. Despite the various etiologies that result in RPL, including cytogenetic abnormalities, antiphospholipid syndrome, uterine anomalies, hereditary thrombophilia, autoimmunity, sperm quality, and environmental factors, the cause of RPL still remains undetermined in the majority of cases.

MicroRNAs (miRNAs) are ∼19--25-nucleotide single-strand non-coding RNA species that induce post-transcriptional gene silencing and mediate translational repression through binding to target mRNA, leading to subsequent mRNA degradation. The recent elucidation of miRNA function has provided new insight into the regulation of gene expression. Key molecules involved in miRNA biogenesis, such as DROSHA, XPO5, and DICER, have been identified in trophoblast cells, confirming that the miRNA biogenesis pathway is active in human placenta [@pone.0095803-Donker1], [@pone.0095803-Forbes1]. It has been demonstrated that the human placenta produces a large number of miRNAs and that those are involved in placental development [@pone.0095803-Fu1]. In addition, miRNAs regulate uterine gene expression associated with inflammatory responses during the peri-implantation period and participate in maternal-fetal immune tolerance [@pone.0095803-Chakrabarty1], [@pone.0095803-Zhu1]. There are numerous reports that demonstrate the association of aberrant miRNA expression with various human diseases related to reproductive conditions [@pone.0095803-Enquobahrie1]--[@pone.0095803-Pan1]. Several studies have reported that genetic polymorphisms are associated with RPL development [@pone.0095803-Choi1]--[@pone.0095803-Kim1]. Furthermore, recent studies have found that nucleotide variations within pri-miRNA molecules affect miRNA processing and result in altered miRNA expression and that a single-nucleotide polymorphism (SNP) in a certain miRNA is associated with litter size in pigs [@pone.0095803-Hu1], [@pone.0095803-Lei1].

Although SNPs have been widely implicated in RPL development, such evidence is lacking for miRNA biogenesis pathway genes. This study was performed to investigate whether polymorphisms in the miRNA machinery genes *DROSHA* (rs10719), *DICER* (rs3742330), *RAN* (rs14035), and *XPO5* (rs11077) are associated with the prevalence of RPL in Korean women. Our previous study investigated the allele frequencies of nine SNPs in those four essential genes in primary ovarian insufficiency and control subjects [@pone.0095803-Rah1]. The results revealed that some polymorphic sites, such as *XPO5* rs3324334 and *XPO5* rs11544382 that had been reported to be polymorphic markers, were monomorphic in all Korean subjects that we genotyped. Therefore, we examined the remaining four polymorphic sites in those four genes.

Materials and Methods {#s2}
=====================

Study participants {#s2a}
------------------

The study was reviewed and approved by the institutional review board (IRB) of CHA Bundang Medical Center in 1999, and written informed consent was obtained from all participants. IRB approved this consent procedure. The study population consisted of Korean participants (Asian) recruited from the Department of Obstetrics and Gynecology of CHA Bundang Medical Center, CHA University (Seongnam-si, South Korea) between March 1999 and February 2010. Participants with a history of smoking, alcohol abuse, cancer, radiation exposure, autoimmune disorder, genetic syndromes, or systemic disease affecting ovarian function, such as diabetes mellitus, were excluded from the study based on medical history and physical examination. Pregnancy loss was diagnosed with hCG testing, ultrasound, and/or physical examination before 20 weeks of gestational age. RPL was defined as two or more consecutive pregnancy losses before 20 weeks of gestational age. All participants in the RPL group experienced recurrent miscarriage with the same partner. RPL patients with previous live births were excluded from this study.

To diagnose idiopathic RPL, we adopted a set of exclusion criteria for the study group. Patients who were diagnosed with RPL due to anatomic, chromosomal, hormonal, infectious, autoimmune, or thrombotic causes were excluded from the study group. To identify anatomic abnormalities in RPL patients, sonography, hysterosalpingogram, hysteroscopy, computerized tomography, and magnetic resonance imaging were used. Karyotyping was performed with standard protocols [@pone.0095803-Barch1]. Hormonal causes included hyperprolactinemia, luteal insufficiency, and thyroid disease and were evaluated by measuring levels of prolactin, thyroid-stimulating hormone, free T4, follicle-stimulating hormone, luteinizing hormone, and progesterone in peripheral blood. Lupus anticoagulant and anticardiolipin antibodies were examined for autoimmune causes such as lupus and antiphospholipid syndrome. Thrombotic causes were defined as thrombophilia and were evaluated by deficiencies of protein C and protein S and by the presence of anti-β2 glycoprotein antibody. The study group consisted of 338 women diagnosed with idiopathic RPL \[age range, 23--43 years; mean age ± standard deviation (SD), 32.81±4.33 years\] ([Table S1](#pone.0095803.s001){ref-type="supplementary-material"}).

The enrollment criteria for the control group included regular menstrual cycles, normal karyotype of 46XX, a history of at least one naturally conceived pregnancy, and no history of pregnancy loss. The control group was comprised of 238 women \[age range, 22--45 years; mean age ± SD, 33.38±5.79 years\]. The average gestational age and number of pregnancy losses in the RPL group were 7.32±1.85 weeks and 3.04±1.61 losses, respectively.

Genotyping {#s2b}
----------

Peripheral blood samples were collected for genotyping. Genomic DNA was extracted from collected blood in the presence of anticoagulant using a G-DEX blood extraction kit (iNtRON Biotechnology, Seongnam-si, Korea). Nucleotide changes were determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis. The PCR primers for this study are shown in [Table S2](#pone.0095803.s002){ref-type="supplementary-material"}. Restriction enzyme digestion was carried out using the following enzymes and conditions: *Nla*III (*DROSHA* rs10719) (New England BioLabs, Ipswich, MA), *Ban*I (*DICER* rs3742330), and *Eco*RI (*XPO5* rs11077) at 37°C for 16 hours and *Bsl*I (*RAN* rs14035) at 55°C for 16 hours. Genotypes determined by RFLP analysis were confirmed by two independent investigators. We confirmed genotypes again by sequencing 10% of the samples by random selection.

Statistical analysis {#s2c}
--------------------

The differences in genotype and allele combination frequencies between idiopathic RPL subjects and controls were compared using the multivariate logistic regression and Fisher\'s exact test, respectively. Allele frequencies were calculated to identify deviations from Hardy--Weinberg equilibrium (HWE) using *P* = .05 as a threshold. Odds ratios (ORs), adjusted odds ratios (AORs), and 95% confidence intervals (CIs) were used to measure the strength of association between genotypes and idiopathic RPL. Two-tailed *P* values \<.05 were considered statistically significant. The ORs were adjusted by the age of the participants because maternal age is a known risk factor for spontaneous abortion and RPL [@pone.0095803-Carp1].

Gene-gene interactions among the SNP loci were analyzed using the log-linear model-based multifactor dimensionality reduction (LM-MDR) and MDR software version 2.0 (available at [www.epistasis.org](http://www.epistasis.org)) [@pone.0095803-Hahn1]--[@pone.0095803-Ritchie1]. The allele combination frequencies for the selected models by MDR analysis were estimated with the HAPSTAT program version 3.0 ([www.bios.unc.edu/\~lin/hapstat](http://www.bios.unc.edu/~lin/hapstat)). The false-positive discovery rate (FDR) correction was used to adjust multiple comparison tests, and associations with FDR-adjusted *P* value \<.05 were considered to be significant data. Statistical analyses were performed with GraphPad Prism 4.0 (GraphPad Software Inc., San Diego, CA) and StatsDirect software version 2.4.4 (StatsDirect Ltd., Altrincham, UK). The statistical power was calculated using G\*POWER 3.9.1 (Institut für Psychologie, Christian-Albrechts-Universität Kiel, Kiel, Germany).

Results {#s3}
=======

The genotypic distribution and allele frequencies of *DROSHA* rs10719, *DICER1* rs3742330, *RAN* rs14035, and *XPO5* rs11077 are shown in [Table 1](#pone-0095803-t001){ref-type="table"}. All of the genes that were analyzed showed polymorphisms and occurred in HWE in both groups. The *DICER* rs3742330, *DROSHA* rs10719, and *XPO5* rs11077 polymorphisms were not associated with the prevalence of RPL. However, the *RAN* rs14035 polymorphism was associated with the prevalence of RPL. The frequency of the CT genotype of *RAN* rs14035 was significantly higher in control subjects than in RPL patients. This association remained statistically significant after FDR correction. Thus, *RAN* rs14035 CT+TT was associated with the decreased prevalence of RPL (AOR = 0.657, 95% CI = 0.469--0.921).

10.1371/journal.pone.0095803.t001

###### Comparison of genotype frequencies of polymorphisms in miRNA machinery genes between RPL and control subjects.

![](pone.0095803.t001){#pone-0095803-t001-1}

  Characteristics              Controls (n = 238)   RPL patients (n = 338)       AOR (95% CI)        *P* [a](#nt102){ref-type="table-fn"}   *P* [b](#nt103){ref-type="table-fn"}   Statistical power (%)
  --------------------------- -------------------- ------------------------ ----------------------- -------------------------------------- -------------------------------------- -----------------------
  ***DICER*** **rs3742330**                                                                                                                                                       
  AA                               75 (31.5)              119 (35.2)           1.000 (reference)                                                                                  
  AG                               123 (51.7)             152 (45.0)         0.741 (0.510--1.077)                   0.117                                  0.234                           42.5
  GG                               35 (14.7)              67 (19.8)          1.196 (0.724--1.975)                   0.484                                  0.776                           12.5
  Dominant (AA vs. AG+GG)                            0.841 (0.590--1.198)            0.336                          0.672                                   15.4                  
  Recessive (AA+AG vs. GG)                           1.428 (0.913--2.235)            0.119                          0.476                                   48.4                  
  HWE *P*                             0.18                  0.147                                                                                                                 
  ***DROSHA*** **rs10719**                                                                                                                                                        
  TT                               110 (46.2)             161 (47.6)           1.000 (reference)                                                                                  
  TC                               108 (45.4)             150 (44.4)         0.943 (0.667--1.335)                   0.742                                  0.977                            6.4
  CC                                20 (8.4)               27 (8.0)          0.919 (0.487--1.733)                   0.794                                  0.794                            5.6
  Dominant (TT vs. TC+CC)                            0.933 (0.669--1.303)            0.685                          0.859                                   7.0                   
  Recessive (TT+TC vs. CC)                           0.907 (0.494--1.665)            0.752                          0.954                                   6.4                   
  HWE *P*                            0.363                  0.329                                                                                                                 
  ***RAN*** **rs14035**                                                                                                                                                           
  CC                               123 (51.7)             210 (62.1)           1.000 (reference)                                                                                  
  CT                               104 (43.7)             113 (33.4)         0.640 (0.452--0.906)                   0.012                                  0.048                           72.6
  TT                                11 (4.6)               15 (4.4)          0.796 (0.354--1.791)                   0.582                                  0.776                           72.5
  Dominant (CC vs. CT+TT)                            0.657 (0.469--0.921)            0.015                          0.060                                   70.0                  
  Recessive (CC+CT vs. TT)                           0.977 (0.439--2.172)            0.954                          0.954                                   4.6                   
  HWE *P*                            0.059                  0.967                                                                                                                 
  ***XPO5*** **rs11077**                                                                                                                                                          
  AA                               197 (82.8)             279 (82.5)           1.000 (reference)                                                                                  
  AC                               39 (16.4)              53 (15.7)          0.993 (0.632--1.561)                   0.977                                  0.977                           50.5
  CC                                2 (0.8)                6 (1.8)           1.896 (0.357--10.061)                  0.453                                  0.776                           12.6
  Dominant (AA vs. AC+CC)                            1.041 (0.670--1.617)            0.859                          0.859                                   53.4                  
  Recessive (AA+AC vs. CC)                          1.911 (0.360--10.140)            0.447                          0.894                                   2.7                   
  HWE *P*                            0.964                  0.072                                                                                                                 

Note: For AOR, OR was adjusted by age of participants. RPL = recurrent pregnancy loss; AOR = adjusted odds ratio; CI = confidence interval; HWE = Hardy--Weinberg equilibrium;

Fisher\'s exact test;

FDR-adjusted *P* value.

The genotype frequencies were stratified according to the number of consecutive pregnancy losses ([Table S3](#pone.0095803.s003){ref-type="supplementary-material"}). For *DROSHA* rs10719 and *XPO5* rs11077, there were no statistically significant differences between the two groups. The *DICER* rs3742330 recessive model (GG compared with AA+AG) was associated with subjects who had history of three or more and four or more pregnancy losses (AOR = 1.718, 95% CI = 1.032--2.861 and AOR = 2.170, 95% CI = 1.181--3.986, respectively), For *RAN* rs14035, the CT genotype was less frequently observed in the subgroups of RPL participants with two or more and four or more consecutive pregnancy losses (AOR = 0.624, 95% CI = 0.412--0.947 and AOR = 0.502, 95% CI = 0.287--0.879, respectively).

We performed combination analyses for miRNA machinery gene polymorphisms that we tested for the study ([Table 2](#pone-0095803-t002){ref-type="table"}). These analyses revealed that the *DICER* rs3742330 GG/*DROSHA* rs10719 TC+CC genotype was significantly more frequent in RPL patients than in control subjects (AOR = 1.990, 95% CI = 1.048--3.778). The frequency of the *DICER* rs3742330 AA+AG/*RAN* rs14035 CT+TT genotype was significantly higher in the control group (AOR = 0.688, 95% CI = 0.475--0.997). In addition, *DROSHA* rs10719 TC+CC/*RAN* rs14035 CT+TT and *RAN* rs14035 CT+TT/*XPO5* rs11077 AA genotypes were more frequently observed in control participants (AOR = 0.621, 95% CI = 0.389--0.991, AOR = 0.631, 95% CI = 0.435--0.914, respectively). Combination analysis according to the number of pregnancy losses was also performed ([Table 3](#pone-0095803-t003){ref-type="table"}). Although these associations with RPL were not significant after FDR correction in combination analysis ([Table 2](#pone-0095803-t002){ref-type="table"}), those associations became more evident when we performed combination analysis according to the number of pregnancy losses even after FDR correction ([Table 3](#pone-0095803-t003){ref-type="table"}). In this combination analysis, there was a significant association between RPL development and the *DICER/DROSHA* GG/TC+CC, *DICER/RAN* GG/CC, and *DICER/XPO5* GG/AC+CC genotypes. The *RAN* CT+TT genotype showed a significant association with RPL when it was combined with the *XPO5* AA genotype. These significances were maintained when we performed multiple comparison correction using FDR, for all except the *RAN/XPO5* CT+TT/AA genotype. Thus, both individual and combined genotyping analysis suggested that both the *DICER* rs3742330 GG and *RAN* rs14035 CC genotypes are associated with RPL prevalence.

10.1371/journal.pone.0095803.t002

###### Combination analysis of polymorphisms of miRNA machinery genes in RPL patients and control participants.

![](pone.0095803.t002){#pone-0095803-t002-2}

  Genotypes             Controls (n = 238)   RPL patients (n = 338)       AOR (95% CI)       *P* [a](#nt105){ref-type="table-fn"}   *P* [b](#nt106){ref-type="table-fn"}   Statistical power (%)
  -------------------- -------------------- ------------------------ ---------------------- -------------------------------------- -------------------------------------- -----------------------
  ***DICER/DROSHA***                                                                                                                                                      
  AA+AG/TT                  90 (37.8)              141 (41.7)          1.000 (reference)                                                                                  
  AA+AG/TC+CC               113 (47.5)             130 (38.5)         0.729 (0.505--1.052)                  0.091                                  0.273                           45.7
  GG/TT                      20 (8.4)               20 (5.9)          0.633 (0.322--1.245)                  0.185                                  0.370                           25.5
  GG/TC+CC                   15 (6.3)              47 (13.9)          1.990 (1.048--3.778)                  0.036                                  0.138                           64.0
  ***DICER/RAN***                                                                                                                                                         
  AA+AG/CC                  107 (45.0)             168 (49.7)          1.000 (reference)                                                                                  
  AA+AG/CT+TT               96 (40.3)              103 (30.5)         0.688 (0.475--0.997)                  0.048                                  0.273                           56.5
  GG/CC                      16 (6.7)              42 (12.4)          1.688 (0.903--3.156)                  0.101                                  0.303                           42.0
  GG/CT+TT                   19 (8.0)               25 (7.4)          0.826 (0.433--1.576)                  0.562                                  0.674                            8.4
  ***DICER/XPO5***                                                                                                                                                        
  AA+AG/AA                  167 (70.2)             226 (66.9)          1.000 (reference)                                                                                  
  AA+AG/AC+CC               36 (15.1)              45 (13.3)          0.963 (0.592--1.566)                  0.878                                  0.905                            5.3
  GG/AA                     30 (12.6)              53 (15.7)          1.308 (0.801--2.137)                  0.283                                  0.425                           20.4
  GG/AC+CC                   5 (2.1)                14 (4.1)          2.055 (0.725--5.822)                  0.175                                  0.350                           32.9
  ***DROSHA/RAN***                                                                                                                                                        
  TT/CC                     60 (25.2)              102 (30.2)          1.000 (reference)                                                                                  
  TT/CT+TT                  50 (21.0)              59 (17.5)          0.694 (0.424--1.137)                  0.147                                  0.294                           37.6
  TC+CC/CC                  63 (26.5)              108 (32.0)         1.024 (0.654--1.604)                  0.917                                  0.917                            5.2
  TC+CC/CT+TT               65 (27.3)              69 (20.4)          0.621 (0.389--0.991)                  0.046                                  0.138                           65.0
  ***DROSHA/XPO5***                                                                                                                                                       
  TT/AA                     90 (37.8)              133 (39.3)          1.000 (reference)                                                                                  
  TT/AC+CC                   20 (8.4)               28 (8.3)          0.945 (0.502--1.781)                  0.861                                  0.905                            5.3
  TC+CC/AA                  107 (45.0)             146 (43.2)         0.914 (0.633--1.319)                  0.631                                  0.757                           73.3
  TC+CC/AC+CC                21 (8.8)               31 (9.2)          1.016 (0.548--1.886)                  0.959                                  0.959                            5.0
  ***RAN/XPO5***                                                                                                                                                          
  CC/AA                     103 (43.3)             177 (52.4)          1.000 (reference)                                                                                  
  CC/AC+CC                   20 (8.4)               33 (9.8)          0.964 (0.525--1.768)                  0.905                                  0.905                            5.1
  CT+TT/AA                  94 (39.5)              102 (30.2)         0.631 (0.435--0.914)                  0.015                                  0.090                           73.3
  T+TT/AC+CC                 21 (8.8)               26 (7.7)          0.708 (0.376--1.334)                  0.285                                  0.428                           17.7

Note: For AOR, OR was adjusted by age of participants. RPL = recurrent pregnancy loss; AOR = adjusted odds ratio; CI = confidence interval.

Fisher\'s exact test;

FDR-adjusted *P* value.

10.1371/journal.pone.0095803.t003

###### Combination analysis of polymorphisms of miRNA machinery genes in RPL patients and control subjects according to the number of previous pregnancy losses.

![](pone.0095803.t003){#pone-0095803-t003-3}

  Genotypes             Controls (n = 238)   PL = 2 (n = 173)       AOR (95% CI)       *P* [a](#nt108){ref-type="table-fn"}   *P* [b](#nt109){ref-type="table-fn"}   Statistical power (%)   PL≥3 (n = 165)       AOR (95% CI)       *P* [a](#nt108){ref-type="table-fn"}   *P* [b](#nt109){ref-type="table-fn"}   Statistical power (%)   PL≥4 (n = 81)       AOR (95% CI)        *P* [a](#nt108){ref-type="table-fn"}   *P* [b](#nt109){ref-type="table-fn"}   Statistical power (%)
  -------------------- -------------------- ------------------ ---------------------- -------------------------------------- -------------------------------------- ----------------------- ---------------- ---------------------- -------------------------------------- -------------------------------------- ----------------------- --------------- ----------------------- -------------------------------------- -------------------------------------- -----------------------
  ***DICER/DROSHA***                                                                                                                                                                                                                                                                                                                                                                                                                                            
  AA+AG/TT                  90 (37.8)           77 (44.5)        1.000 (reference)                                                                                                             64 (38.8)       1.000 (reference)                                                                                                             25 (30.9)       1.000 (reference)                                                                                  
  AA+AG/TC+CC               113 (47.5)          67 (38.7)       0.705 (0.458--1.086)                  0.113                                  0.170                           53.7              63 (38.2)      0.767 (0.492--1.196)                  0.242                                  0.363                           52.6              34 (42.0)     1.083 (0.603--1.946)                   0.789                                  0.871                           38.7
  GG/TT                      20 (8.4)            8 (4.6)        0.478 (0.199--1.148)                  0.099                                  0.170                           58.5               12 (7.3)      0.815 (0.371--1.789)                  0.610                                  0.610                           13.5               6 (7.4)      1.088 (0.393--3.009)                   0.871                                  0.871                            6.3
  GG/TC+CC                   15 (6.3)           21 (12.1)       1.596 (0.765--3.327)                  0.213                                  0.213                           33.6              26 (15.8)      2.460 (1.202--5.036)                  0.014                                  0.042                           82.9              16 (19.8)     4.084 (1.752--9.520)                   0.001                                  0.003                           97.2
  ***DICER/RAN***                                                                                                                                                                                                                                                                                                                                                                                                                                               
  AA+AG/CC                  107 (45.0)          91 (52.6)        1.000 (reference)                                                                                                             77 (46.7)       1.000 (reference)                                                                                                             38 (46.9)       1.000 (reference)                                                                                  
  AA+AG/CT+TT               96 (40.3)           53 (30.6)       0.672 (0.433--1.043)                  0.077                                  0.231                           60.5              50 (30.3)      0.721 (0.459--1.130)                  0.154                                  0.231                           46.4              21 (25.9)     0.615 (0.336--1.124)                   0.114                                  0.171                           56.9
  GG/CC                      16 (6.7)           18 (10.4)       1.330 (0.641--2.763)                  0.444                                  0.444                           17.8              24 (14.5)      2.095 (1.041--4.220)                  0.038                                  0.114                           68.0              15 (18.5)     2.731 (1.223--6.098)                   0.014                                  0.042                           75.3
  GG/CT+TT                   19 (8.0)            11 (6.4)       0.687 (0.311--1.520)                  0.354                                  0.444                           27.0               14 (8.5)      0.996 (0.467--2.121)                  0.991                                  0.991                            5.2               7 (8.6)      1.035 (0.400-- 2.681)                  0.943                                  0.943                            5.0
  ***DICER/XPO5***                                                                                                                                                                                                                                                                                                                                                                                                                                              
  AA+AG/AA                  167 (70.2)          123 (71.1)       1.000 (reference)                                                                                                             103 (62.4)      1.000 (reference)                                                                                                             50 (61.7)       1.000 (reference)                                                                                  
  AA+AG/AC+CC               36 (15.1)           21 (12.1)       0.834 (0.462--1.508)                  0.549                                  0.762                           16.0              24 (14.5)      1.113 (0.624--1.982)                  0.718                                  0.718                           10.4              9 (11.1)      0.838 (0.375--1.872)                   0.666                                  0.666                           13.4
  GG/AA                     30 (12.6)           24 (13.9)       1.095 (0.610--1.967)                  0.762                                  0.762                            8.9              29 (17.6)      1.552 (0.881--2.733)                  0.128                                  0.192                           46.2              15 (18.5)     1.671 (0.833--3.354)                   0.148                                  0.222                           40.3
  GG/AC+CC                   5 (2.1)             5 (2.9)        1.277 (0.359--4.537)                  0.706                                  0.762                            9.0               9 (5.5)       2.909 (0.948--8.925)                  0.062                                  0.186                           61.0               7 (8.6)      4.661 (1.417--15.330)                  0.011                                  0.033                           75.5
  ***DROSHA/RAN***                                                                                                                                                                                                                                                                                                                                                                                                                                              
  TT/CC                     60 (25.2)           54 (31.2)        1.000 (reference)                                                                                                             48 (29.1)       1.000 (reference)                                                                                                             21 (25.9)       1.000 (reference)                                                                                  
  TT/CT+TT                  50 (21.0)           31 (17.9)       0.706 (0.394--1.262)                  0.240                                  0.360                           38.8              28 (17.0)      0.685 (0.377--1.248)                  0.216                                  0.324                           42.2              10 (12.3)     0.553 (0.236--1.296)                   0.173                                  0.309                           55.0
  TC+CC/CC                  63 (26.5)           55 (31.8)       0.983 (0.585--1.651)                  0.947                                  0.947                            5.9              53 (32.1)      1.087 (0.638--1.851)                  0.760                                  0.760                           10.0              32 (39.5)     1.534 (0.790--2.975)                   0.206                                  0.309                           44.7
  TC+CC/CT+TT               65 (27.3)           33 (19.1)       0.587 (0.335--1.029)                  0.063                                  0.189                           72.1              36 (21.8)      0.678 (0.389--1.181)                  0.170                                  0.324                           50.0              18 (22.2)     0.794 (0.385--1.633)                   0.530                                  0.530                           20.1
  ***DROSHA/XPO5***                                                                                                                                                                                                                                                                                                                                                                                                                                             
  TT/AA                     90 (37.8)           74 (42.8)        1.000 (reference)                                                                                                             59 (35.8)       1.000 (reference)                                                                                                             24 (29.6)       1.000 (reference)                                                                                  
  TT/AC+CC                   20 (8.4)            11 (6.4)       0.684 (0.308--1.521)                  0.351                                  0.629                           27.8              17 (10.3)      1.261 (0.610--2.607)                  0.532                                  0.946                           16.0               7 (8.6)      1.269 (0.478--3.368)                   0.632                                  0.632                           11.8
  TC+CC/AA                  107 (45.0)          73 (42.2)       0.838 (0.545--1.287)                  0.419                                  0.629                           22.2              73 (44.2)      1.015 (0.651--1.583)                  0.946                                  0.946                            5.9              41 (50.6)     1.438 (0.807--2.561)                   0.217                                  0.471                           40.7
  TC+CC/AC+CC                21 (8.8)            15 (8.7)       0.904 (0.431--1.894)                  0.789                                  0.789                            9.4               16 (9.7)      1.130 (0.542--2.355)                  0.745                                  0.946                            9.6              9 (11.1)      1.599 (0.641--3.988)                   0.314                                  0.471                           27.5
  ***RAN/XPO5***                                                                                                                                                                                                                                                                                                                                                                                                                                                
  CC/AA                     103 (43.3)          96 (55.5)        1.000 (reference)                                                                                                             81 (49.1)       1.000 (reference)                                                                                                             44 (54.3)       1.000 (reference)                                                                                  
  CC/AC+CC                   20 (8.4)            13 (7.5)       0.703 (0.331--1.491)                  0.358                                  0.358                           25.6              20 (12.1)      1.233 (0.620--2.453)                  0.551                                  0.551                           14.4              9 (11.1)      1.015 (0.426--2.419)                   0.973                                  0.973                            4.6
  CT+TT/AA                  94 (39.5)           51 (29.5)       0.592 (0.381--0.920)                  0.020                                  0.060                           79.8              51 (30.9)      0.682 (0.436--1.066)                  0.093                                  0.279                           56.4              21 (25.9)     0.522 (0.289--0.943)                   0.031                                  0.093                           76.9
  CT+TT/AC+CC                21 (8.8)            13 (7.5)       0.687 (0.323--1.462)                  0.330                                  0.358                           27.9               13 (7.9)      0.709 (0.326--1.542)                  0.385                                  0.551                           22.8               7 (8.6)      0.666 (0.249--1.781)                   0.418                                  0.627                           22.9

Note: For AOR, OR was adjusted by age of participants. RPL = recurrent pregnancy loss; PL = number of pregnancy losses; AOR = adjusted odds ratio; CI = confidence interval; HWE = Hardy--Weinberg equilibrium.

Fisher\'s exact test;

FDR-adjusted P value.

To evaluate whether gene-gene interaction models exert synergistic effects on RPL risk, we conducted MDR-based allele combinations of four polymorphisms of miRNA machinery genes ([Table 4](#pone-0095803-t004){ref-type="table"} and [Table S4](#pone.0095803.s004){ref-type="supplementary-material"}). We selected two interaction models (*DICER*/*DROSHA*/*RAN*/*XPO5* and *DICER*/*DROSHA*) because their CV values were 10/10. Among the models of four polymorphic loci in *DICER*/*DROSHA*/*RAN*/*XPO5*, four allele combinations (A-T-C-A, A-T-T-C, G-T-C-C, and G-C-T-A) showed synergistic effects on increased RPL risk (OR = 1.510, 95% CI = 1.161--1.965; OR = 20.858, 95% CI = 1.240--350.756; OR = 12.117, 95% CI = 0.697--210.595; and OR = 29.759, 95% CI = 1.794--493.586, respectively), while A-T-C-C, A-C-T-A, and G-T-T-A were associated with reduced RPL risk (OR = 0.366, 95% CI = 0.189--0.709; OR = 0.466, 95% CI = 0.281--0.773; and OR = 0.533, 95% CI = 0.335--0.850, respectively). However, it was difficult to make a conclusion with four allele combinations (*DICER/DROSHA/RAN/XPO5*) of A-T-T-C, G-T-C-C, and G-C-T-A due to the wide range of confidence intervals. Among the models of two loci, the A-T and G-C allele combinations in the *DICER*/*DROSHA* model were associated with increased prevalence of RPL (OR = 1.292, 95% CI = 1.017--1.643 and OR = 1.694, 95% CI = 1.182--2.426, respectively), whereas A-C was associated with reduced RPL risk (OR = 0.615, 95% CI = 0.451--0.839). [Table S5](#pone.0095803.s005){ref-type="supplementary-material"} represents the statistical power of the significant genotype. In addition, we conducted power analysis to detect the associations in the case-control study at the 5% significance level. The power varies for an OR by the proportion of exposure (i.e., the target genotype) in the control. A total sample size of 576 (338 RPL cases vs. 238 controls) could have reasonable power to detect an OR of 1.7 when the proportions of exposure in the control were 20% (power = 76.3%), 30% (power = 84.9%), and 40% (power = 87.7%). Additionally, this sample size has reasonable power to detect an OR of 0.55 for the proportions of 20% (power = 73.1%), 30% (power = 85.6%), and 40% (power = 91.3%) in the control. Furthermore, this sample size might have sufficient power to detect an OR of 1.7 or greater and an OR of 0.55 or less. However, the power will be smaller when it is compared with multiple genotypes.

10.1371/journal.pone.0095803.t004

###### Allele combination analysis of miRNA machinery genes in RPL patients and control participants using the multifactor dimensionality reduction method.

![](pone.0095803.t004){#pone-0095803-t004-4}

  Allele combination             Controls (n = 238)   RPL patients (n = 338)         OR (95% CI)         *P* [a](#nt111){ref-type="table-fn"}   *P* [b](#nt112){ref-type="table-fn"}   Statistical power (%)
  ----------------------------- -------------------- ------------------------ ------------------------- -------------------------------------- -------------------------------------- -----------------------
  ***DICER/DROSHA/RAN/XPO5***                                                                                                                                                         
  A-T-C-A                              0.2455                  0.33             1.510 (1.161--1.965)                    0.002                                  0.010                           71.4
  A-T-C-C                              0.0548                 0.0211            0.366 (0.189--0.709)                    0.003                                  0.010                           70.0
  A-T-T-A                              0.0726                 0.0636            0.856 (0.539--1.359)                    0.552                                  0.589                           11.5
  A-T-T-C                              0.0001                 0.021            20.858 (1.240--350.756)                  0.001                                  0.008                            8.6
  A-C-C-A                              0.1175                 0.0874            0.717 (0.487--1.055)                    0.110                                  0.176                           31.7
  A-C-C-C                              0.0057                 0.0143            2.367 (0.648--8.651)                    0.259                                  0.345                           26.8
  A-C-T-A                              0.0812                 0.0395            0.466 (0.281--0.773)                    0.003                                  0.010                           66.6
  A-C-T-C                              0.0067                   0               0.100 (0.005--1.942)                    0.070                                  0.140                           16.6
  G-T-C-A                              0.2176                 0.195             0.868 (0.650--1.159)                    0.336                                  0.384                           16.4
  G-T-C-C                                0                    0.0114           12.117 (0.697--210.595)                  0.024                                  0.055                  
  G-T-T-A                              0.0893                 0.0504            0.533 (0.335--0.850)                    0.008                                  0.021                           59.4
  G-T-T-C                              0.0092                 0.0057            0.702 (0.175--2.823)                    0.724                                  0.724                           12.3
  G-C-C-A                              0.086                  0.1077            1.284 (0.859--1.920)                    0.231                                  0.336                           21.5
  G-C-C-C                              0.0083                 0.0215            2.678 (0.883--8.121)                    0.098                                  0.174                           37.0
  G-C-T-A                                0                    0.0302           29.759 (1.794--493.586)                 \<.0001                                 0.002                  
  G-C-T-C                              0.0056                 0.0011            0.234 (0.024--2.254)                    0.313                                  0.384                            9.1
  ***DICER/DROSHA***                                                                                                                                                                  
  A-T                                  0.3761                 0.4373            1.292 (1.017--1.643)                    0.039                                  0.052                           43.8
  A-C                                  0.208                  0.1397            0.615 (0.451--0.839)                    0.002                                  0.008                           69.3
  G-T                                  0.313                  0.261             0.773 (0.596--1.001)                    0.054                                  0.054                           38.9
  G-C                                  0.1029                 0.1621            1.694 (1.182--2.426)                    0.004                                  0.008                           67.9

Note: ORs and 95% CIs of each allele combinations were calculated with reference to frequencies of all others using Fisher\'s exact test. *P* value by Fisher\'s exact test. RPL = recurrent pregnancy loss; AOR = adjusted odds ratio; CI = confidence interval.

Fisher\'s exact test;

FDR-adjusted *P* Value.

Discussion {#s4}
==========

We evaluated four SNPs in *DICER*, *DROSHA*, *XPO5*, and *RAN*, which are essential for miRNA biogenesis [@pone.0095803-Kim2], [@pone.0095803-Sung1]. Our results comparing differences in genotype frequencies in miRNA machinery genes revealed that *DICER* rs3742330 GG genotype had significant associations with RPL in Korean women when it was combined with the *DROSHA* rs10719 TC+CC genotype. In addition, the ORs of RPL prevalence were higher because patients who possessed the *DICER* rs3742330 GG/*DROSHA* rs10719 TC+CC genotype experienced more pregnancy loss. Defective DICER function due to genetic polymorphism might be intensified by *DROSHA* polymorphisms. These two molecules are considered major regulators of miRNA biogenesis. However, there is no evidence that these molecules interact with each other. It remains unclear how genetic polymorphisms in these genes influence each other. To elucidate the mechanisms by which different alleles of *DICER* or *DROSHA* affect RPL development, additional functional studies should be performed. Although the exact mechanism could not be elucidated in the present study, our finding might be used in the future as a marker to predict RPL development in women with a spontaneous abortion.

Dicer is essential in miRNA biogenesis, and its function has been reported to be involved reproduction. Dicer expression is detected in female reproductive organs, including the ovary, oviduct, and uterus [@pone.0095803-Hong1]--[@pone.0095803-Otsuka1]. Female mice with general hypomorphic mutation of *Dicer* were infertile because of luteal deficiency [@pone.0095803-Otsuka1]. The conditional knockout of *Dicer* within ovarian granulosa cells affects ovulation rate by influencing the number of preovulatory follicles that achieve proper development [@pone.0095803-Hong1], [@pone.0095803-Nagaraja1]. On the other hand, Dicer is reported to be involved in regulating placental growth by influencing pro-mitogenic signaling molecules through miRNA action [@pone.0095803-Clague1].

Although there is limited evidence that polymorphisms of *DICER* alter biologic functions depending on alleles, a number of studies have reported that *DICER* polymorphisms, including rs3742330, affect disease development and patient survival in various cancers [@pone.0095803-Clague1]--[@pone.0095803-Lin1]. In addition, the functional analysis of the *DICER* rs1057035 SNP, which resides in the 3′UTR of *DICER*, has revealed that targeting of has-miR-574-3p to *DICER* was differentially affected by the type of *DICER* rs1057035 allele and that the *DICER* rs1057035 variant C allele led to reduced expression of Dicer [@pone.0095803-Ma1]. In the *DICER* gene, the polymorphic site *DICER* rs3742330A\>G, found in the 3′ UTR of *DICER*, is considered to be important for mRNA transcript stability. In terms of human reproduction, *DICER* rs12323635, located in promoter region of *DICER*, has been reported to decrease the risk of oligozoospermia [@pone.0095803-Qin1]. Therefore, Dicer is likely to be a crucial molecule for pregnancy.

There are several potential mechanisms that explain why *DICER* polymorphisms are associated with miscarriage. *DICER* polymorphism may affect decidualization of the endometrium and induce implantation defects in embryos, resulting in recurrent miscarriage. Decidualization of endometrial stroma is one of the crucial steps for trophoblast invasion and placenta development [@pone.0095803-Gellersen1]. A recent study using human embryonic stem cells demonstrated that DICER expression increased during *in vitro* decidualization. DICER inhibition affected the expression of decidual markers and transcription factors---such as PRL and HOXA10---which play a role during decidualization [@pone.0095803-Estella1]. Second, *DICER* polymorphisms may have an influence on placental development by affecting miRNA expression involving cytotrophoblast proliferation. Cytotrophoblasts are trophoblastic stem cells that play multiple roles [@pone.0095803-Fu1]. Recent research has demonstrated enhanced proliferation of cytotrophoblasts without exogenous growth factors following Dicer knock-down in first-trimester placenta. Although the miRNAs affecting cell proliferation were not identified, the authors suggested that Dicer-dependent miRNA affected the proliferation of cytotrophoblasts [@pone.0095803-Forbes1]. Dicer polymorphisms induce aberrant expression of miRNAs regulating cytotrophoblast proliferation, possibly resulting in abnormal placental development and abortion. Finally, the miRNA expression affected by the *DICER* polymorphism may induce chromosome mis-segregation, leading to aneuploidy, which is the most common cause of miscarriage. The centrosome is known to be a source of aneuploidy. The extra centrosome forms a multipolar spindle during mitosis in a mother cell, resulting in aneuploid daughter cells. This pathogenesis has been shown in cancer development [@pone.0095803-Holland1]. miR-210 overexpression is reported to induce centrosome amplification in renal cancer [@pone.0095803-Nakada1]. Therefore, aberrant miRNA expression may cause chromosomal aneuploidy in cancer. A similar mechanism exists by which abnormal miRNA expression may cause aneuploid embryos and recurrent miscarriage during early development. A significant association between the *RAN* rs14035 genotype and RPL prevalence was observed when it was combined with the *XPO5* rs11077 AA genotype. Ran, which is a member of the Ras superfamily of GTPases, is essential for the translocation of pre-miRNAs from the nucleus to the cytoplasm through the nuclear pore complex [@pone.0095803-Lund1]. Xpo5 mediates nuclear export of pre-miRNA in a RAN GTP-dependent manner by binding to pre-miRNA and RAN GTPase in the nucleus [@pone.0095803-Lund1]. Although several reports have shown the association of these molecules with disease development in various cancers, no report has elucidated the role of these molecules in human reproduction [@pone.0095803-Lin2], [@pone.0095803-Ye1].

Our previous study revealed that the *XPO5* rs2257082 allele was more frequently observed in premature ovarian insufficiency (POI) patients than in control subjects [@pone.0095803-Rah1]. However, we could not identify any association between *RAN* polymorphism and POI development. Additionally, *RAN* rs14035, but not *XPO5* rs11077, exerted an effect on RPL development. Regarding both molecules, few reports have evaluated the clinical significance of SNPs not only in cancer but also in pregnancy-related disease. In addition, no study has elucidated the functions of those SNPs in miRNA biogenesis. Therefore, additional functional studies are required to elucidate how *RAN* rs14035 affects disease promotion and prevention depending on its genotype.

We obtained contrasting results regarding RPL development in the combination analysis for the *DROSHA* rs10719 TC+CC genotype. When it was combined with *DICER* rs3724330 GG genotype, RPL development was more frequently observed in RPL group. When the *DROSHA* rs10719 TC+CC genotype was combined with the *RAN* rs14035 CT+TT genotype, RPL development was rare in the RPL group. One potential explanation for this observation is that idiopathic RPL has various unknown etiologies. Many reports in the literature have demonstrated that several causes are associated with recurrent miscarriage, such as angiogenesis, immunologic factors, and miRNAs [@pone.0095803-Jeon1], [@pone.0095803-Hu1], [@pone.0095803-Lee2]. This may explain why the same polymorphism affects disease development differently. The result of our combination analysis of polymorphisms according to the number of pregnancy losses supports this explanation ([Table 3](#pone-0095803-t003){ref-type="table"}). The AORs increased as the number of previous pregnancy losses increased in patients who have the *DROSHA* rs10719 TC+CC genotype combined with the *DICER* rs3742330 GG genotype (1.596 vs. 2.460 vs. 4.084). Conversely, no such tendency was noted with the *DROSHA* TC+CC/*RAN* CT+TT genotype. Instead, the effect of polymorphisms was attenuated as the number of miscarriages increased. This suggests that genetic polymorphisms with respect to miRNA machinery genes were associated with disease development not through a common pathway but through various pathogeneses.

There are several potential limitations in this study. First, this case-control study only shows an association between SNPs in miRNA machinery genes and RPL development, not a causal relationship. Therefore, it is difficult to conclude that miRNA machinery genes affect recurrent miscarriage. Second, the manner in which polymorphisms in miRNA biogenesis pathway genes affect RPL development is still unclear, and a functional study of those SNPs to elucidate the pathogenesis related to RPL was not conducted. Third, the lack of information regarding placental pathology, immunologic profiles, and miRNA expression could have contributed to the investigation of potential roles of miRNA machinery genes during the peri-implantation and early pregnancy periods. Lastly, the sample size of the control group is relatively small, compared with that of the study group. This is because we included all eligible cases during the study period to avoid selection bias. This difference in sample size will increase type 2 errors in the genetic association study. To reduce the bias, we compared the *RAN* rs14035 and *XPO5* rs11077 genotype frequencies in the control group with those from other studies that were performed in Korea. The genotype frequencies of *RAN* rs14035 and *XPO5* rs11077 in the control group of our study showed similar patterns to the results in the control groups of previous reports regarding lung cancer and breast cancer in Korea [@pone.0095803-Kim2], [@pone.0095803-Sung1].

Recent groundbreaking discoveries that small, non-coding RNAs can regulate gene expression transcriptionally or post-transcriptionally and that these RNAs are involved in placental development through trophoblast differentiation, proliferation, and angiogenesis provide us with insight into the pathogenesis of idiopathic RPL [@pone.0095803-Donker1], [@pone.0095803-Chakrabarty1], [@pone.0095803-Dai1]. To the best of our knowledge, this is the first report to investigate the association between polymorphisms in miRNA biogenesis machinery genes and the prevalence of RPL in a Korean population and suggests that genetic polymorphisms in miRNA biogenesis machinery genes show a relationship with the risk of RPL. The present study may contribute to assessments of individual risk of RPL. However, further epidemiologic studies with larger subject numbers should be performed to confirm and expand our results. In addition, the results of our study warrant further functional studies to elucidate the mechanisms by which polymorphisms of miRNA machinery genes affect RPL development.
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